Lenabasum for Diffuse Cutaneous Systemic Sclerosis
Lenabasum is being developed for diffuse cutaneous SS as a tablet to be taken twice per day. It works by binding to immune cells and triggers a process which reduces inflammation and the scaring and thickening of tissues which usually happens in SS. If licensed, lenabasum has the potential to reduce the scaring which happens in diffuse cutaneous SS and improve symptoms.
Tocilizumab (RoActemra) for Adults with Giant Cell Arteritis – intravenous injection
Tocilizumab is a disease modifying drug that acts by blocking specific proteins that signal the inflammatory processes affecting blood vessels in GCA. It is currently licensed for the treatment of GCA in adults as a subcutaneous (under the skin) injection, but reactions at the place of injection include redness, itching and pain. It is anticipated that these reactions would be avoided if the drug was given as an intravenous infusion.
AR101 peanut allergy immunotherapy for adult and paediatric patients
AR101 is a form of treatment for peanut allergy. This treatment is administered orally with the aim of reeducatingthe body’s immune system, in order to increase the level at which the body reacts to peanuts, or toreduce the allergic response. The drug is targeted at adults and children with severe peanut allergy.Phase III clinical trials …
Dupilumab for bilateral nasal polyposis and chronic sinusitis – second line
Dupilumab is a new drug to treat nasal polyps, which are swellings in the lining of the nose and sinuses (air-filled spaces behind the nose, eyes and cheeks). They can cause a blocked or runny nose, and may reduce the sense of smell. Dupilumab is injected under the skin and may help reduce nasal symptoms. …